Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs
Restricted accessResearch articleFirst published online June, 2014
Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs
Mutant huntingtin (HTT) protein is the cause of Huntington's disease (HD), an incurable neurological disorder. Almost all patients are heterozygous for mutant HTT and approaches that reduce levels of mutant HTT while leaving expression of wild-type HTT intact might be ideal options for therapeutic development. We have developed several allele-selective strategies for silencing HTT, including single-stranded silencing RNAs (ss-siRNAs). ss-siRNAs are oligonucleotides containing chemical modifications that permit action through the RNA interference (RNAi) pathway. Modified ss-siRNAs chosen to test the effects of varying oligomer length, lipid modification, the introduction of mismatched bases, and variation of chemical modification. We find that several modified ss-siRNA are potent and allele-selective inhibitors of HTT expression. An ss-siRNA with three mismatched bases relative to the CAG repeat was an allele-selective inhibitor of HTT expression in the HdhQ175 mouse model. Multiple allele-selective ss-siRNAs provide a wide platform of modifications to draw on for further optimization and therapeutic development. Our data provide insights into how ss-siRNAs can be modified to improve their properties and facilitate the discovery of the lead compounds necessary for further development.
Get full access to this article
View all access options for this article.
References
1.
AIBAY., HUJ., LIUJ., XIANGQ., MARTINEZC., and COREYD.R. (2014). Effect of unlocked nucleic acids (UNA) modifications on RNAi and allele-selective inhibition of huntingtin and ataxin-3. Biochemistry, 52, 9329–9338.
2.
BOUDREAUR.L., MCBRIDEJ.L., MARTINSI., SHENS., XINGY., CARTERB.J., and DAVIDSONB.L. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther., 17, 1053–1063.
3.
CARROLLJ.B., WARBYS.C., SOUTHWELLA.L., DOTYC.N., GREENLEES., SKOTTEN., HUNGG., BENNETTC.F., FREIERS.M., and HAYDENM.R. (2011). Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele specific silencing of mutant huntingtin. Mol. Ther., 19, 2178–2185.
4.
CHENX., WUJ., LUOX., SUPNETC., KIMM.W., LOTZG.P., YANGG., MUCHOWSKIP.J., KODADEKT., and BEZPROZVANNYI. (2011). Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of huntington's disease. Chem. Biol., 18, 1113–11125.
5.
DIFIGLIAM., SENA-ESTEVESM., CHASEK., SAPPE., PFISTERE., SASSM., YODERJ., REEVESP., PANDEYR.K., RAJEEVK.G., et al. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A., 104, 17204–17209.
6.
DISNEYM.D. (2102). DISNEY, M.D. (2102). Rational design of chemical genetics probes of RNA function and lead therapeutics targeting repeating transcripts. Drug Discov. Today, 18, 1228–1236.
7.
DUYAOM., AMBROSEC., MYERSR., NOVELLETTOA., PERSICHETTIF., FRONTALIM., FOLSTEINS., ROSSC., FRANZM., ABBOTTM., et al. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet., 4, 387–392.
8.
EVERSM.M., PEPERSB.A., VAN DEUTEKOMJ.C., DEN DUNNENJ. T., VAN OMMENG.J., and VAN ROON-MOMW. M. (2011). Targeting several cag expansion diseases with a single antisense oligonucleotide. PLoS One, 6, e24308.
9.
FISZERA., MYKOWSKAA., and KRYZOSIAKW.J. (2011). Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res., 39, 5578–5585.
10.
GAGNONK. T., PENDERGRAFFH., DELEAVEYG., SWAYZEE., POTIERP., RANDOLPHJ., ROESCHE., CHATTOPADHYAYAJ., DAMHAM., BENNETTC.F., et al. (2010). Allele-selective silencing of huntingtin expression with antisense oligonucleotides targeting the mRNA expanded CAG repeat. Biochemistry, 49, 10166–10178.
11.
HEIKKINENT., LEHTIMAKIK., VARTIANENN., PUOLIVALIJ., HENDRICKSS.J., GLASERJ.R., BRADAIAA., WADELK., TOULLERC., KONTKANANENO., et al. (2102). Characterization of neurophysiologic and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One, 7, e50717.
12.
HUJ., MATSUIM., GAGNONK.T., SCHWARTZJ.C., GABILLETS., ARARK., WUJ., BEZPROZVANNYI., and COREYD.R. (2009). Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol., 27, 478–484.
13.
HUJ., LIUJ., and COREYD.R. (2010). Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183–1188.
14.
HUJ., LIUJ., CHUY., YUD., and COREYD. R. (2012). Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats. Nucleic Acids Res., 40, 11270–11280.
15.
KORDASIEWICZH.B., STANEKL.M., WANCEWICZE.V., MAZURC., MCALONISM.M., PYTELK.A., ARTATESJ.W., CHENGS.H., SHIHABUDDINL.S., HUNGG., et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of mutant huntingtin synthesis. Neuron, 74, 1031–1044.
16.
KREMERB., GOLDBERGP., ANDREWS.E., THEILMANNJ., TELENIUSH., ZEISLERJ., SQUITIERIF., LINB., BASSETTA., ALMQUISTE., et al. (1994). A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med., 330, 1401–1406.
17.
LAGIER-TOURENNEC., BAUGHNM., RIGOF., SUNS., LIUP., LIH.R., JIANGJ., WATTA.T., CHUNS., KATZM., et al. (2013). Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U. S. A., 110, e4530–4539.
LIUJ., YUD., AIBAY., PENDERGRAFFH., SWAYZEE.E., LIMAW.F., PRAKASHT.P., and COREYD.R. (2013a). ss-siRNAs allele-selectively inhibit ataxin-3 expression: Multiple mechanisms for an alternative gene silencing strategy. Nucl. Acids Res., 41, 9570–9583.
20.
LIUJ., PENDERGRAFFH., NARAYANANNAIRK.J., LACKEYJ.G., KUCHIMANCHIS., RAJEEVK.G., MANOHARANM., HUJ., COREYD.R (2013b). RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucl. Acids Res., 41, 8788–8801.
21.
MACDONALDM.E., AMBROSEC.M., DUYAOM.P., MYERSR.H., LINC., SRINIDHIL., BARNESG., TAYLORS.A., JAMESM., GROOTN., et al. The Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971–983.
22.
MATSUIM., and COREYD.R. (2012). Allele selective inhibition of trinucleotide repeats. Drug Discov. Today, 17, 443–450.
23.
MENALLEDL.B., KUDWAA.E., MILLERS., FITZPATRICKJ., WATSON-JOHNSONJ., KEATINGN., RUIZM., MUSHLINR., ALSOSIOW., MCCONNELLK., et al. (2012). Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One, 7, e49838.
24.
NANCEM.A., and MYERSR.H. (2001). Juvenile onset Huntington's disease—clinical and research perspectives. MRDD Res. Rev., 7, 153–157.
25.
OSTERGAARDM.E., SOUTHWELLA.L., KORDASIEWICZH., WATTA.T., SKOTTEN.H., DOTYC.N., VAIDK., VILLANUEVAE.B., SWAYZEE.E., BENNETTC.F., et al. (2013). Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele-selective suppression of mutant huntingtin in the CNS. Nucleic Acids Res., 41, 9634–9650.
26.
ORRH.T., and ZOGBHIH.Y. (2007). Trinucleotide repeat disorders. Ann. Rev. Neurosci., 30, 575–621.
27.
PFISTERE.L., KENNINGTONL., STRAUBHAARJ., WAGHS., LIUW., DIFIGLIAM., LANDWEHRMEYERB., VONSATTELJ.P., ZAMOREP.D., and ARONINN. (2009). Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol., 19, 774–778.
28.
SAHD.W., and ARONINN. (2011). Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest., 121, 500–507.
29.
SCHWARZD.S., DINGH., KENNINGTONL., MOOREJ.T., SCHELTERJ., BURCHARDJ., LINSLEYP.S., ARONINN., XUZ., and ZAMOREP.D. (2006). Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2, e140.
YUD., PENDERGRAFFH., LIUJ., KORDASIEWICZH.B., CLEVELANDD. W., SWAYZEE., LIMAW., CROOKES. T., PRAKASHT., and COREYD. R. (2012). Single-stranded RNAs that function through RNAi are potent and allele-selective inhibitors of huntingtin expression. Cell, 150, 895–908.
